December 10 | 2013
ROCHE TAKES OVER DEVELOPMENT OF SAVIRA’S INFLUENZA POLYMERASE INHIBITOR PROGRAMS
Savira pharmaceuticals GmbH announces that Roche (SIX: RO, ROG; OTCQX: RHHBY) will take sole development responsibility for Savira’s influenza polymerase inhibitor programs.
October 30 | 2012
ANDREAS HAUER JOINING SAVIRA PHARMACEUTICALS AS CFO
Andreas Hauer has 16 years of experience in financial services, management consultancy, and biotechnology industry with particular strengths in corporate finance.
June 4 | 2012
SAVIRA SIGNS COLLABORATION AND LICENSE AGREEMENT WITH ROCHE
Savira pharmaceuticals GmbH announces alliance with Roche (SIX: RO, ROG; OTCQX: RHHBY) to develop small molecule polymerase inhibitors for the treatment of influenza virus infections.
November 7 | 2011
SAVIRA PHARMACEUTICALS AWARDED GRANT BY THE TECHNOLOGY AGENCY OF THE CITY OF VIENNA (ZIT) FOR THE DEVELOPMENT OF DUAL INFLUENZA POLYMERASE INHIBITORS
Savira pharmaceuticals receives funding of 458,125 EUR from the Technology Agency of the City of Vienna (ZIT) for the development of novel influenza therapeutics with dual mechanism of action. Based on Savira’s experience in the design of mono-selective inhibitors of the influenza polymerase cap-binding and endonuclease active site – both targets are involved in the so-called cap-snatching mechanism – the company now aims at the design of a therapeutic capable of targeting both domains by one single molecular structure. With this approach, Savira not only expects to improve potency of their flu polymerase inhibitors but also anticipates a further reduction in antiviral drug resistance.
August 19 | 2011
INTERVIEW WITH BIOCENTURY
Savira’s CEO, Oliver Szolar, gave an Interview to Stephan Hansen from BioCentury.
In this article, Oliver Szolar announced PoC for an influenza polymerase cap binding inhibitor from Savira’s focused compound library in a lethal mouse pneumonia model.
August 20 | 2010
SAVIRA PHARMACEUTICALS AWARDED GRANTS BY THE EUROPEAN COMMISSION AND THE AUSTRIAN RESEARCH PROMOTION AGENCY FOR THE DEVELOPMENT OF NOVEL INFLUENZA THERAPEUTICS
Savira receives funding as part of a consortium under the lead of the European Molecular Biology Laboratory (EMBL) that has been awarded a grant from the European Commission of EUR 6 million. Earlier this year, Savira received funding of kEUR 560 from the Austrian Research Promotion Agency (FFG) supporting its flu polymerase inhibitor development program.
July 29 | 2010
TOP MEDICINAL CHEMISTRY EXPERT HELMUT H. BUSCHMANN TO JOIN SAVIRA PHARMACEUTICALS AS CSO
Helmut H. Buschmann is a leading medicinal chemistry and senior management executive with 19 years of international experience in drug discovery research and drug development in the pharmaceutical and biotechnology industry with particular strengths in identifying, evaluating, and integrating pre-clinical projects and transfer to clinical development.
October 16 | 2009
SAVIRA AMONG THE MOST PROMISING VIENNA START-UP COMPANIES
Savira was awarded third place by the City of Vienna Future Award
September 23 | 2009
FOUNDATION OF SAVIRA PHARMACEUTICALS GMBH
Savira, an Austrian pharmaceutical company focusing on the development of novel anti-influenza drugs was recently established in Vienna and supported with seed financing of 1 Mio Euro by the AWS (Austria Wirtschaftsservice). Based on intellectual property from the co-founders, the European Molecular Biology Laboratory (EMBL) from Heidelberg, Germany and the biotech company onepharm from Vienna, Austria, Savira will manage a medicinal chemistry program aiming at the identification of lead candidates and the development of anti-influenza drugs.